Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03559569

Acronym

Seneshock

Enrollment

520

Registered

2018-06-18

Start date

2019-01-07

Completion date

2028-03-31

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Infection, Shock

Keywords

Shock, Cardiovascular Diseases, Infection

Brief summary

Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease. The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections. The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.

Interventions

BIOLOGICALBiological samples will be done to evaluate the endothelial and leukocyte senescence.

Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Circulatory shock * patient with health care insurance

Exclusion criteria

* Patients' refusal to participate in clinical research * Pregnant woman * Breastfeeding woman * A patient with a protective order

Design outcomes

Primary

Measure	Time frame	Description
The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells.	1 year	Biological samples will be done to evaluate the endothelial and leukocyte senescence.

Secondary

Measure	Time frame
Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states	5 years

Countries

France

Contacts

Primary ContactMorgane CLERC

morgane.clerc@chru-strasbourg.fr03 88 11 68 55

Backup ContactMadoé JULIANS

madoe.julians@chru-strasbourg.fr03 88 11 61 86

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026